Search results
Showing 7786 to 7800 of 8314 results
Access to a range of journals, databases and other evidence-based resources for health and social care staff in England.
NICE is committed to supporting the national agenda for achieving a sustainable health and care system.
The key stages in development of our quality standards
A timeline showing where in the NICE evaluation process companies will be charged.
Learn from NICE International, part of the UK's National Institute for Health and Care Excellence, about how to improve your nation's health and wellbeing
Hundreds of people set to benefit after life-extending lung cancer treatment given green light
Targeted immunotherapy found to significantly increase overall survival rates for people with an aggressive form of lung cancer has been recommended by NICE.
Our modular updates framework ensures flexibility and consistency in updating our manuals and helps prioritise important updates.
Home What NICE does Our research work {"@context":"http://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1
We assess the efficacy and safety of interventional procedures used for treatment or diagnosis to determine whether they work well enough and are safe enough for use in the NHS.
NICE wants as many people as possible to be able to use our services, and we have designed it to be accessible.
NICE work with the NHS, patients and carers, healthcare professionals and organisations to help put our guidance into practice.
International collaboration with NICE
Breakthrough life-extending combination treatment for advanced bladder cancer recommended by NICE
The new treatment offers hope to thousands living with advanced urothelial cancer, with clinical trials showing overall survival rates were almost twice as long compared to standard treatment.
First NICE-curated guideline announced ahead of World Duchenne Awareness Day
In the lead-up to World Duchenne Awareness Day on Sunday 7 September, we’re pleased to announce the completion of our first assessment of an externally developed clinical guideline.
Recommendations in NICE’s type 2 diabetes guideline update, published today, will enhance the use of SGLT-2 inhibitors in primary care and address these health inequalities.